Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...

Novo Nordisk (NVO) is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

He added that the US market relies heavily on generic drugs rather than branded products, which Novo Nordisk does not sell. Competitor Eli Lilly (LLY) recently announced a $27 billion investment ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.